The primary purpose of this new role is to establish and manage the development process for the ABPI Code.
Applications close midnight 5th May.
Pharmaceutical companies are doing everything in their power to avoid disruption to the supply of medicines in all Brexit scenarios. This includes increasing stocks of medicine in the UK, changing supply routes, transferring medicine licenses and duplicating testing in the EU.
A rare disease is officially classified as a condition that affects less than 5 in 10,000 in the general population, but smaller numbers of patients should not mean less focus on treating them.
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
Illness never sleeps. It grows, mutates and causes pain and suffering. Disease never takes a break, so neither do we. Because people fighting disease deserve the best chance to live. We won’t rest until people around the world see a brighter tomorrow.
Millions of people wouldn't be here today if it wasn't for life-changing science. And many more wouldn't be living the lives they do.
11 April 2019
In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
13 March 2019
“Pharmaceutical companies have done everything in their power to prepare for a ‘no deal’ Brexit. This includes increasing stocks of medicines, changing and adding new supply routes and duplicating manufacturing processes here and in Europe." MORE >
08 March 2019
King’s College London, Wellcome and pharmaceutical company MSD announced a collaboration and licencing deal today that could lead to a new class of pain medications.
27 February 2019
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
17 April 2019
The ABPI sponsors the Andrew Blake Tribute Award, which recognises the significant contributions of animal technologists to improving laboratory animal welfare. This year we congratulate Stephen Woodley and Stuart Newman for winning the 2019 Award.
21 March 2019
The ABPI and Health Innovation Manchester were shortlisted for ‘Best Pharmaceutical Partnership’ in the HSJ partnership awards last night. Partnership working with the NHS is the way forward, says ABPI Chief Executive Mike Thompson.